Search
Candoxatril
go.drugbank.com/drugs/DB00616ExperimentalCandoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.
Sulfametopyrazine
go.drugbank.com/drugs/DB00664ApprovedWithdrawnLong-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.
Amelubant
go.drugbank.com/drugs/DB06248InvestigationalSynonyms: Carbamic acid, N-[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy]phenyl]iminomethyl]-, ethyl esterAbexinostat
go.drugbank.com/drugs/DB12565InvestigationalAbexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others.
AGS-004
go.drugbank.com/drugs/DB05742InvestigationalThis approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.
MVA-BN-brachyury-TRICOM vaccine
go.drugbank.com/drugs/DB17424InvestigationalMVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. … [L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine.
Synonyms: MVA-BN-Brachyury, MVA-BN-Brachyury Prime VaccineIndium In-111 satumomab pendetide
go.drugbank.com/drugs/DB00057ApprovedWithdrawnTumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors. Satumomab Pendetide (trade name: OncoScint®) is no longer commercially available.
Synonyms: Indium In 111 satumomab pendetideKC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascula...
Sonpiretigene isteparvovec
go.drugbank.com/drugs/DB17844InvestigationalSonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. … Developed by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP).